PROFILE |
 |
AVI BioPharma (formerly Antivirals, Inc.) develops therapeutic and gene-targeted treatments for cancer and heart disease. Its lead product, Avicine, reacts against the human chorionic gonadotropin (hCG) hormone, which is present in most cancers; the drug continues in clinical trials, specifically for cancer of the colon, prostate, and pancreas. AVI's gene-targeted drugs, NEU-GENES, block the function of certain genetic sequences to treat bone cancer and restenosis, a cardiovascular disease. The firm has also licensed XenoMouse technology from Abgenix to develop antibodies as companions to Avicine. Biotech firm SuperGen has bought the marketing rights to Avicine.
COMPETITION |
 |
Boehringer Ingelheim GmbH (dossier)
Bristol-Myers Squibb Company (BMY)
GlaxoSmithKline plc (GSK)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 1.30
1-Yr. Sales Growth: 1,200.0%
Employees: 71
Revenue per employee: $18,309.86
KEY PEOPLE |
 |
Denis R. Burger
CEO
Mark M. Webber
CFO
CONTACT INFO |
 |
1 SW Columbia, Ste. 1105
Portland, OR 97258
US
Phone: 503-227-0554
Fax: 503-227-0751
Online: Web Site
|